Figure 2

Changes in forced vital capacity (FVC) during nintedanib treatment for idiopathic pulmonary fibrosis. Differences in the annual rate of FVC decline between patients with nausea and those without (A) and between patients with diarrhea and those without (B). The red line shows the average FVC decline for patients with the adverse effect, while the blue line shows the average FVC decline for patients without the adverse effect.